Qingchi San ((sic)) treats ulcerative colitis in mice by inhibiting the nuclear factor-kappa B signaling pathway and Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 inflammasome formation

OBJECTIVE: To investigate the efficacy of Qingchi San ((sic), QCS), a preparation of Traditional Chinese Medicine, on ulcerative colitis (UC)in mice by inhibiting the nuclearfactor-kappa B (NF-Kappa B) signaling pathway and nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) infla-mmasome formation. METHODS: The UC model was established with male C57BL/6J as the animal model. Bodyweight, Disease Activity Index (DAI), colon length and weight were detected. Furthermore, colonic histology was performed by hematoxylin-eosin (HE) staining. interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), myeloperoxidase (MPO) and superoxide dismutase (SOD) were performed by enzyme-linked immunosorbent assay. Cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS) mRNA expression were conducted by real-time quantitative polymerase chain reaction (RT-qPCR). NF-Kappa B, inhibitor of NF-Kappa B alpha (i Kappa B alpha), Phosphorylated inhibitor of NF-Kappa B alpha (p-i Kappa B alpha), caspase-1, NLRP3 and Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) protein expression were conducted by Western blotting. RESULTS: Compared with UC model group, Bodyweight was significantly increased in QCS treatment. At the same time, DAI was significantly decreased in QCS treatment. Colon length and weight and colonic histology were significantly improved in QCS treatment. Furth-ermore, the expression of IL-1 beta, IL-6, TNF-alpha, MPO, SOD, COX2, and iNOS were significantly decreased in QCS treatment. Finally, the expression of NF-Kappa B signaling pathway-related proteins NF-Kappa B, i Kappa B alpha, p-i Kappa B alpha, and the expression of NLRP3 inflammasome related proteins caspase-1, NLRP3 and ASC were significantly decreased in QCS treatment. CONCLUSION: Traditional Chinese drug QCS could treat UC by inhibiting the NF-Kappa B signaling pathway and NLRP3 inflammasome formation in mice.(c) 2023 JTCM. All rights reserved.